Ajinomoto Co Inc (2802)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Ajinomoto Co Inc (2802) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013429
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ajinomoto Co Inc (Ajinomoto) is a food products company that focuses on foods, bioscience fine chemicals and pharmaceuticals and health. It carries out research and development and production of seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. The company also provides solutions for improved food resources, human health and global sustainability. Ajinomoto is also involved in wellness, packaging, logistics, and other services. The company has operations in Europe, Africa, Japan, Asia and Americas. Ajinomoto is headquartered in Tokyo, Japan.

Ajinomoto Co Inc (2802) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Ajinomoto Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Ajinomoto Co Inc, Medical Devices Deals, 2011 to YTD 2017 9
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Eisai Forms Joint Venture with Ajinomoto 11
Althea Technologies Enters Into Co-Marketing Agreement With Sherpa Clinical 12
Licensing Agreements 13
Allena Pharma Amends Licensing Agreement With Althea Technologies 13
Ajinomoto North America Enters Into Licensing Agreement With Global Pharma Company For Corynex 14
Acquisition 15
Ajinomoto to Acquire GeneDesign 15
Ajinomoto Completes Acquisition Of Althea Technologies For US$175 Million 16
Ajinomoto Co Inc – Key Competitors 18
Ajinomoto Co Inc – Key Employees 19
Ajinomoto Co Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 23
Recent Developments 24
Other Significant Developments 24
Apr 13, 2017: Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Ajinomoto Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Ajinomoto Co Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Ajinomoto Co Inc, Medical Devices Deals, 2011 to YTD 2017 9
Ajinomoto Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Eisai Forms Joint Venture with Ajinomoto 11
Althea Technologies Enters Into Co-Marketing Agreement With Sherpa Clinical 12
Allena Pharma Amends Licensing Agreement With Althea Technologies 13
Ajinomoto North America Enters Into Licensing Agreement With Global Pharma Company For Corynex 14
Ajinomoto to Acquire GeneDesign 15
Ajinomoto Completes Acquisition Of Althea Technologies For US$175 Million 16
Ajinomoto Co Inc, Key Competitors 18
Ajinomoto Co Inc, Key Employees 19
Ajinomoto Co Inc, Subsidiaries 21
Ajinomoto Co Inc, Joint Venture 23

★海外企業調査レポート[Ajinomoto Co Inc (2802)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TUV Nord AG:企業の戦略的SWOT分析
    TUV Nord AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Rox Resources Limited:企業の戦略・SWOT・財務情報
    Rox Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Rox Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Toronto Hydro Corporation:企業の戦略的SWOT分析
    Toronto Hydro Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Zimmer Biomet Holdings Inc (ZBH):企業の財務・戦略的SWOT分析
    Zimmer Biomet Holdings Inc (ZBH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • National Bank of Egypt S.A.E:企業の戦略・SWOT・財務情報
    National Bank of Egypt S.A.E - Strategy, SWOT and Corporate Finance Report Summary National Bank of Egypt S.A.E - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Vermillion Inc (VRML):医療機器:M&Aディール及び事業提携情報
    Summary Vermillion Inc (Vermillion) is a medical device company that discovers, develops and markets diagnostic and bio-analytical solutions that supports physicians to diagnose, treat and improve gynecologic health outcomes for women. The company’s in vitro diagnostic test OVA1, a simple blood test …
  • Merus NV (MRUS):企業の財務・戦略的SWOT分析
    Summary Merus NV (Merus) discovers and develops antibody therapeutics for cancer indications. The company is investigating MCLA-128, for the treatment of metastatic breast cancer and solid tumors; MCLA-117 designed to harness and activate T-cells to kill CLEC12A-expressing acute myeloid leukemia (AM …
  • Repsol, S.A.:企業の戦略・SWOT・財務分析
    Repsol, S.A. - Strategy, SWOT and Corporate Finance Report Summary Repsol, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • AbbVie Inc (ABBV):企業の財務・戦略的SWOT分析
    AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Methanol Chemicals Co (2001):企業の財務・戦略的SWOT分析
    Methanol Chemicals Co (2001) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Bonvests Holdings Limited:戦略・SWOT・企業財務分析
    Bonvests Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bonvests Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Targovax ASA (TRVX):企業の財務・戦略的SWOT分析
    Summary Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline …
  • BEKB | BCBE Private Banking:企業の戦略・SWOT・財務情報
    BEKB | BCBE Private Banking - Strategy, SWOT and Corporate Finance Report Summary BEKB | BCBE Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • A. K. Capital Services Ltd (530499):企業の財務・戦略的SWOT分析
    A. K. Capital Services Ltd (530499) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • High Arctic Energy Services Inc (HWO):企業の財務・戦略的SWOT分析
    Summary High Arctic Energy Services Inc (High Arctic) operates as an oil and gas company that provides drilling services and equipment for rentals. The company provides services such as drilling services, matting and equipment rentals, snubbing services and nitrogen services. It offers equipment ren …
  • Chongqing Lummy Pharmaceutical Co Ltd (300006):製薬・医療:M&Aディール及び事業提携情報
    Summary Chongqing Lummy Pharmaceutical Co Ltd (Lummy) is a pharmaceutical company that provides pharmaceutical ingredients and drugs and related products. The company’s products include antibacterial drugs, antifungal drugs, tumor drugs, immune system agents, blood system agents, cardiovascular syst …
  • Bank of Ayudhya Public Co Ltd (BAY):企業の財務・戦略的SWOT分析
    Bank of Ayudhya Public Co Ltd (BAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Bank Saint Petersburg:企業の戦略・SWOT・財務情報
    Bank Saint Petersburg - Strategy, SWOT and Corporate Finance Report Summary Bank Saint Petersburg - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Applied Materials Inc (AMAT):企業の財務・戦略的SWOT分析
    Applied Materials Inc (AMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Lucigen Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Lucigen Corp (Lucigen), a subsidiary of LGC Ltd, is a medical device company that discovers, manufactures, and commercializes molecular biology product. The company’s products comprise competent cells, nextgen seq, enzymes, cloning systems, PCR and amplification, cloning test kits and vector …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆